Four different study groups also explored the synergistic effects of pembrolizumab/lenvatinib combinational treatment in patients with unresectable HCC, as lenvatinib is a potent FDA-approved receptor tyrosine kinase inhibitor (TKI) for the first-line treatment of patients with unresectable HCC [34]. The gene discussed is NTRK1; the disease is hepatocellular carcinoma.